Management of hypertension in overweight and obese patients: A practical guide for clinicians

被引:25
作者
Dentali, F [1 ]
Sharma, AM [1 ]
Douketis, JD [1 ]
机构
[1] St Josephs Hosp, Hamilton, ON L8N 4A6, Canada
基金
美国国家卫生研究院;
关键词
D O I
10.1007/s11906-005-0065-5
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The association between obesity and cardiovascular disease is well established, and up to 60% of overweight or obese patients have hypertension. Dietary interventions associated with modest weight loss are effective in controlling blood pressure and in reducing use of antihypertensive drug therapy in overweight and obese patients. However, long-term maintenance of weight loss is achieved only in a small proportion of patients. Orlistat and sibutramine may help to achieve and maintain weight loss but may not be sufficient to control blood pressure in overweight and obese hypertensive patients. Consequently, antihypertensive drug therapy is often necessary in addition to weight loss interventions. Few studies have investigated different anti hypertensive drugs, specifically in overweight and obese patients with hypertension. Based on studies involving obese and nonobese patients, first-line treatment options include a diuretic alone or an angiotensin-converting enzyme (ACE) inhibitor alone. If monotherapy is inadequate for blood pressure control, combination therapy with diuretic and ACE inhibitor and/or combining either of these drugs with a calcium channel blocker are reasonable treatment options. Additional studies to further clarify the management of these patients are warranted.
引用
收藏
页码:330 / 336
页数:7
相关论文
共 45 条
[1]  
*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[2]  
[Anonymous], 2003, CONTR GLOB OB EP
[3]   Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension [J].
Bakris, G ;
Calhoun, D ;
Egan, B ;
Hellmann, C ;
Dolker, M ;
Kingma, I .
JOURNAL OF HYPERTENSION, 2002, 20 (11) :2257-2267
[4]   Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled [J].
Bramlage, P ;
Pittrow, D ;
Wittchen, HU ;
Kirch, W ;
Boehler, S ;
Lehnert, H ;
Hoefler, M ;
Unger, T ;
Sharma, AM .
AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (10) :904-910
[5]   Comparison of the Atkins, Ornish, Weight watchers, and Zone diets for weight loss and heart disease risk reduction [J].
Dansinger, ML ;
Gleason, JA ;
Griffith, JL ;
Selker, HP ;
Schaefer, EJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (01) :43-53
[6]   Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients [J].
Derosa, G ;
Cicero, AFG ;
Murdolo, G ;
Piccinni, MN ;
Fogari, E ;
Bertone, G ;
Ciccarelli, L ;
Fogari, R .
DIABETES OBESITY & METABOLISM, 2005, 7 (01) :47-55
[7]  
Donato KA, 1998, ARCH INTERN MED, V158, P1855, DOI 10.1001/archinte.158.17.1855
[8]   Metabolic and weight loss effects of long-term dietary intervention in obese patients: Four-year results [J].
Flechtner-Mors, M ;
Ditschuneit, HH ;
Johnson, TD ;
Suchard, MA ;
Adler, G .
OBESITY RESEARCH, 2000, 8 (05) :399-402
[9]   Prevalence and trends in obesity among US adults, 1999-2000 [J].
Flegal, KM ;
Carroll, MD ;
Ogden, CL ;
Johnson, CL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (14) :1723-1727
[10]   A randomized trial of a low-carbohydrate diet for obesity [J].
Foster, GD ;
Wyatt, HR ;
Hill, JO ;
McGuckin, BG ;
Brill, C ;
Mohammed, BS ;
Szapary, PO ;
Rader, DJ ;
Edman, JS ;
Klein, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (21) :2082-2090